Bristol R&D Success Shows Link Between Licensing And First-Cycle Approval

Bristol-Myers Squibb's heavy reliance on in-licensing products in the first half of the decade appears to have paid off with a high number of new molecular entity submissions and a relatively strong first-cycle approval record